Contact this trialFirst, we need to learn more about you.
Janus Kinase (JAK) Inhibitor
Selinexor + Ruxolitinib for Myelofibrosis
Recruiting1 awardPhase 3
New Haven, Connecticut
This trial is testing a new combination drug therapy for myelofibrosis, a bone marrow cancer. The trial will have three phases, with the first two phases testing safety and preliminary efficacy in various doses, and the third phase testing efficacy in a randomized study.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service